» Articles » PMID: 30956444

- and - Expression in Clinical No Response-antimonial Isolates

Overview
Journal J Parasit Dis
Specialty Parasitology
Date 2019 Apr 9
PMID 30956444
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Cutaneous leishmaniasis (CL) is a major disease in many parts of the world. Since no vaccine has been developed, treatment is the best way to control it. In most areas, antimonial resistance whose mechanisms have not been completely understood has been reported. The main aim of this study is gene expression assessing of - and - in clinical isolates. The patients with CL from central and north Iran were considered for this study. The samples were transferred in RNAlater solution and stored in - 20 °C. RNA extraction and cDNA synthesis were performed. The gene expression analysis was done with SYBR Green real-time PCR using ∆∆CT. Written informed consent forms were filled out by patients, and then, information forms were filled out based on the Helsinki Declaration. Statistical analysis was done with SPSS (16.0; SPSS Inc, Chicago) using independent test, Shapiro-Wilk, and Pearson's and Spearman's rank correlation coefficients. ≤ 0.05 was considered significant. The gene expression of and had no relation with sex and age. The gene expression was high in sensitive isolates obtained from north of the country. The gene expression was significant in sensitive and no response-antimonial isolates from the north, but no significant differences were detected in sensitive and resistant isolates from central Iran. Differential gene expression of and in various clinical resistances isolates in different geographical areas shows multifactorial ways of developing resistance in different isolates.

Citing Articles

Leishmania spp. genetic factors associated with cutaneous leishmaniasis antimony pentavalent drug resistance: a systematic review.

Nery R, Santos T, Gois L, Barral A, Khouri R, Feitosa C Mem Inst Oswaldo Cruz. 2024; 119:e230240.

PMID: 39230137 PMC: 11370656. DOI: 10.1590/0074-02760230240.


Molecular characteristic of treatment failure clinical isolates of .

Eslami G, Hatefi S, Ramezani V, Tohidfar M, Churkina T, Orlov Y PeerJ. 2021; 9:e10969.

PMID: 33763300 PMC: 7956003. DOI: 10.7717/peerj.10969.


Isolation and Molecular Identification of spp. Agents in Patients with Cutaneous Leishmaniasis in Yazd Province, Endemic Region of Central Iran.

Eslami G, Bafghi A, Lotfi M, Mirzaei F, Ahmadi S, Tajfirouzeh A Iran J Public Health. 2020; 49(5):975-980.

PMID: 32953686 PMC: 7475624.


Relationship of Leishmania RNA Virus (LRV) and treatment failure in clinical isolates of Leishmania major.

Abtahi M, Eslami G, Cavallero S, Vakili M, Hosseini S, Ahmadian S BMC Res Notes. 2020; 13(1):126.

PMID: 32178715 PMC: 7074996. DOI: 10.1186/s13104-020-04973-y.

References
1.
Herwaldt B . Leishmaniasis. Lancet. 1999; 354(9185):1191-9. DOI: 10.1016/S0140-6736(98)10178-2. View

2.
Paule M, White R . Survey and summary: transcription by RNA polymerases I and III. Nucleic Acids Res. 2000; 28(6):1283-98. PMC: 111039. DOI: 10.1093/nar/28.6.1283. View

3.
Lee T, Young R . Transcription of eukaryotic protein-coding genes. Annu Rev Genet. 2000; 34:77-137. DOI: 10.1146/annurev.genet.34.1.77. View

4.
Legare D, Cayer S, Singh A, Richard D, Papadopoulou B, Ouellette M . ABC proteins of Leishmania. J Bioenerg Biomembr. 2002; 33(6):469-74. DOI: 10.1023/a:1012870904097. View

5.
Clayton C . Life without transcriptional control? From fly to man and back again. EMBO J. 2002; 21(8):1881-8. PMC: 125970. DOI: 10.1093/emboj/21.8.1881. View